Approvals (Drugs@FDA)

LAMLIQUE

AZURITY · LAMOTRIGINE HEMIFUMARATE

NDA221109Drug (NDA)Prescription
Open FDA's page for this record
Application number
NDA221109
Sponsor name
AZURITY
Submissions
  1. Submission type
    ORIG
    Submission number
    1
    Submission status
    AP
    Submission status date
    20260925
    Review priority
    STANDARD
    Submission class code
    TYPE 2
    Submission class code description
    Type 2 - New Active Ingredient
    Application docs
    1. ID
      87317
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/221109Orig1s000ltr.pdf
      Date
      20260929
      Type
      Letter
    2. ID
      87354
      Url
      https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/221109Orig1s000lbl.pdf
      Date
      20261006
      Type
      Label
Products
  1. Product number
    001
    Reference drug
    Yes
    Brand name
    LAMLIQUE
    Reference standard
    Yes
    Dosage form
    SUSPENSION
    Route
    ORAL
    Marketing status
    Prescription
    Active ingredients
    1. Name
      LAMOTRIGINE HEMIFUMARATE
      Strength
      EQ 5MG BASE/ML
  2. Product number
    002
    Reference drug
    Yes
    Brand name
    LAMLIQUE
    Reference standard
    Yes
    Dosage form
    SUSPENSION
    Route
    ORAL
    Marketing status
    Prescription
    Active ingredients
    1. Name
      LAMOTRIGINE HEMIFUMARATE
      Strength
      EQ 25MG BASE/ML
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.